The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10611 malaria professionals are enjoying the free benefits of MalariaWorld today

Mefloquine

Choice of and Adherence to Prophylactic Antimalarials

July 5, 2011 - 08:19 -- Kabogo Ndegwa
Author(s): 
Larry Goodyer, Leanne Rice and Alan Martin
Reference: 
Journal of Travel Medicine, Volume 18, Issue 4, pages 245–249, July/August 2011

A shorter post-travel regimen has a significant impact on adherence to antimalarial prophylaxis. A reassessment of the risk by travelers on returning home may be a major contributor to this poor adherence.

Medical Condition: 
Medical Treatment: 

Open Access | Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice

June 7, 2011 - 07:30 -- Kabogo Ndegwa
Author(s): 
Dow GS, Milner E, Bathurst I, Bhonsle J, Caridha D, Gardner S, Gerena L, Kozar M, Lanteri C, Mannila A, McCalmont W, Moon J, Read KD, Norval S, Roncal N, Shackleford DM, Sousa J, Steuten J, White KL, Zeng Q, Charman SA
Reference: 
Malaria Journal 2011, 10:150 (6 June 2011)

Reduction of CNS levels of NGQMs relative to mefloquine may be feasible. Optimization of this property together with potency and long half-life may be feasible amongst diamine quinoline methanols.

Medical Condition: 
Medical Treatment: 

2,4-Diarylthiazole antiprion compounds as a novel structural class of antimalarial leads

June 2, 2011 - 07:06 -- Kabogo Ndegwa
Author(s): 
Mark J. Thompson, Jennifer C. Louth, Susan M. Little, Beining Chen, Iain Coldham
Reference: 
Bioorganic & Medicinal Chemistry Letters, Volume 21, Issue 12, 15 June 2011, Pages 3644-3647

A significant intersection between antimalarial and antiprion activity is well established for certain compound classes, specifically for polycyclic antimalarial agents bearing basic nitrogen-containing sidechains (e.g., chloroquine, quinacrine, mefloquine).

Medical Condition: 

Plasmodium falciparum Infection during Suppressive Prophylaxis with Mefloquine Does Not Induce an Antibody Response to Merozoite Surface Protein-1(42)

May 5, 2011 - 09:30 -- Patrick Sampao
Author(s): 
James E. Moon, Gregory A. Deye, Lori Miller, Susan Fracisco, R. Scott Miller, Donna Tosh, James F. Cummings, Colin Ohrt, AND Alan J. Magill
Reference: 
Am J Trop Med Hyg, May 2011; 84: 825 - 829.

We conclude that malaria infection during suppressive prophylaxis does not induce antibody response to the blood-stage antigen MSP142 in a malaria-naïve study population.

Medical Treatment: 

A single, low, oral dose of a 5-carbon-linked trioxane dimer orthoester plus mefloquine cures malaria-infected mice

April 27, 2011 - 11:06 -- Kabogo Ndegwa
Author(s): 
Deuk Kyu Moon, Abhai Tripathi, David Sullivan, Maxime A. Siegler, Sean Parkin, Gary H. Posner
Reference: 
Bioorganic & Medicinal Chemistry Letters, Volume 21, Issue 9, 1 May 2011, Pages 2773-2775

Four 5-carbon-linked trioxane dimer orthoesters (6a–6d) have been prepared in 4 or 5 chemical steps from the natural trioxane artemisinin (1).

Medical Condition: 
Medical Treatment: 

Efficacy and safety of mefloquine, artesunate, mefloquine–artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial

January 26, 2011 - 09:47 -- Patrick Sampao
Author(s): 
Phonepasong Soukhathammavong, Peter Odermatt, Jennifer Keiser, et al.
Reference: 
The Lancet Infectious Diseases, Volume 11, Issue 2, February 2011, Pages 110-118

We did a randomised open-label trial between February and April, 2010, in the Saysetha district, Attapeu Province, Laos. Eligible patients were school children aged 10–15 years who had O viverrini infections.

Schistosoma mansoni: Schistosomicidal effect of mefloquine and primaquine in vitro

January 3, 2011 - 09:14 -- Kabogo Ndegwa
Author(s): 
M.C. Holtfreter, M. Loebermann, S. Klammt, M. Sombetzki, P. Bodammer, D. Riebold, R. Kinzelbach, E.C. Reisinger
Reference: 
Experimental Parasitology, Volume 127, Issue 1, January 2011, Pages 270-276

We investigated the effects of the anti-malarials mefloquine and primaquine against the juvenile and adult life stages of Schistosoma mansoni in vitro.

Review: Open Access | The position of mefloquine as a 21st century malaria chemoprophylaxis

December 16, 2010 - 07:35 -- Kabogo Ndegwa
Author(s): 
Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein H
Reference: 
Malaria Journal 2010, 9:357 (9 December 2010)

The choice of anti-malarial drug should be an evidence-based decision that considers the profile of the individual traveller and the risk of malaria.

Person: 
Organization: 
Medical Condition: 
Medical Treatment: 

Open Access | Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum

December 1, 2010 - 05:15 -- Kabogo Ndegwa
Author(s): 
Pradines B, Briolant S, Henry M, Oeuvray C, Baret E, Amalvict R, Didillon E, Rogier C
Reference: 
Malaria Journal 2010, 9:339 (25 November 2010)

There was an absence of cross-resistance between pyronaridine and quinolines, and the IC50 values for pyronaridine were found to be unrelated to mutations in the transport protein genes pfcrt, pfmdr1, pfmrp or pfnhe-1, known to be involved in quinoline resistance.

Medical Treatment: 

Open Access | Anti-bacterial activity of intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of sulphadoxine-pyrimethamine, mefloquine, and azithromycin

November 3, 2010 - 08:09 -- Kabogo Ndegwa
Author(s): 
Capan M, Mombo-Ngoma G, Makristathis A, Ramharter M
Reference: 
Malaria Journal 2010, 9:303 (29 October 2010)

These data indicate important differences in the spectrum of anti-bacterial activity for the evaluated anti-malarial drugs.

Medical Condition: 

Pages

Subscribe to RSS - Mefloquine